Table 1 sMer, sTyro3 and sAxl ELISA demographic data

Number (%) female

9 (60%)

22 (73%)

11 (79%)

Ethnicity, number

White British

10

21

10

Asian

5

9

4

Age at sampling, mean (range) years

14.2 (3.5 – 18.7)

14.0 (7.5 - 17.9)

15.5 (10.7-19.4)

Disease duration, mean (range) years

3.0 (0.4 – 9.1)

3.1 (0 – 11.8)

3.5 (0 – 11.5)

Biomarker/disease activity parameter, mean (range)

ESR, mm/hour (normal 2-8 mm/hour)

15 (1 – 60)

18.5 (<1 – 108)

12.6 (1-50)

CRP, mg/litre (normal 0-8 mg/litre)

11.2 (<4 – 78.9)

6.4 (<4 – 43.3)

4.1 (4-5.6)

C3, gm/litre (normal 1.1 – 1.9)

0.8 (0.5 – 1.4)

1.3 (0.6 – 10.9)

1.1 (0.4 – 1.4)

C4, gm/litre (normal 0.19 – 0.56)

0.14 (0.09 – 0.34)

0.15 (0.08 – 0.46)

0.2 (0.05 – 0.5)

Anti-dsDNA titre, IU/ml (normal <7)

3.1 (14 – 32)

4.9 (0 – 58)

424 (0 – 5408)

C-HAQ score, 0-3, mean (range)

0.27 (0.13 – 2.38)

0.44 (0 – 2.38)

0.64 (0 – 2.25)

Physician’s global assessment of disease activity by VAS, mean (range) mm

19 (5 – 80)

19.4 (0 – 85)

25 (0 – 70)

BILAG-2004

Number with grade A or grade B

5

11

6

Score, mean (range)

2.6 (1 – 15)

2.9 (0 – 19)

3.8 (0 – 9)

Current medications, number of patients

Hydroxychloroquine

13

19

10

Methotrexate

0

3

0

Azathioprine

3

4

3

Mycophenolate mofetil

8

13

7

Prednisolone

11

13

6

Prednisolone dosage, mean (range) mg/day

7.4 (1 – 30)

14.4 (3 – 40)

15.8 (2 – 60)

Rituximab

1

0

1

Infliximab

1

2

2